Publikationen in Zusammenarbeit mit Forschern von Hospital Clinic Barcelona (6)

2021

  1. Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

2017

  1. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

    Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153

2016

  1. Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)

    Annals of Oncology, Vol. 27, pp. vi213

2012

  1. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

2005

  1. Bortezomib is an efficient agent in plasma cell leukemias

    International Journal of Cancer, Vol. 114, Núm. 4, pp. 665-667

  2. Genetic abnormalities and patterns of antigenic expression in multiple myeloma

    Clinical Cancer Research, Vol. 11, Núm. 10, pp. 3661-3667